权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Aminopeptidases for Neurotoxic Pyroglutamate Beta-Amyloid of Alzheimers Disease

氨基肽酶治疗阿尔茨海默病的神经毒性焦谷氨酸β-淀粉样蛋白

基本信息

批准号：
8690732
负责人：
Vivian Y. H Hook
金额：
$ 19.38万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN DIEGO
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-07-01 至 2017-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8690732
关键词：
Address Alanine Alzheimer&apos s Disease Amino Acids Aminopeptidase Amyloid beta-Protein Aspartate Behavioral Brain Brain region Cattle Cell Death Cells Chromaffin Cells Clinical Collection Cyclization Data Development Disease Drug Targeting Enzymes Event Excision Functional disorder Future Gene Expression Gene Silencing Glutamates Goals Hippocampus (Brain)Human Human Genome Immunoprecipitation Investigation Isoenzymes Knock-out Lead Mass Spectrum Analysis Memory Memory Loss Memory impairment Microscopy Modeling Modification Molecular Cloning Mus N-terminal Nerve Degeneration Neuroblastoma Neurons Peptide Hydrolases Peptides Production Property Pyroglutamate Rattus Regulation Role Secretory Vesicles Senile Plaques Severities Small Interfering RNA Therapeutic Agents Toxic effect Transgenic Organisms Ubenimex United States National Institutes of Health alanine aminopeptidase amastatin amyloid peptide base glutaminyl-peptide cyclotransferase glutamyl aminopeptidase improved inhibitor/antagonist mouse model neuron loss neurotoxic neurotoxicity new technology normal aging novel peptide A peptide hormone public health relevance small molecule

项目摘要

DESCRIPTION (provided by applicant): The N-terminal truncated pyroglutamate (pGlu) modified forms of beta-amyloid (A ¿), pGluA ¿ (3-40/42) (referred to as pGluA ¿), display high neurotoxicity, neurodegeneration and memory loss in Alzheimer's disease. Notably, pGluA ¿ is abundant in AD brains and is present at levels greater than A¿ (1-40/42). The pGluA ¿ accelerates formation of A¿ and pGluA ¿ oligomers that cause neurotoxic cell death and memory deficits in AD. The pGluA ¿ (3-40/42) peptides begin with N-terminal glutamate, the third amino acid of A¿ (1-40/42). pGluA¿ peptides are generated from A ¿ (1-40/42) by aminopeptidases that remove the N-terminal aspartate and alanine residues, followed by cyclization of the N-terminal glutamate. The aminopeptidases required to generate pGluA¿ peptides have not yet been elucidated. Therefore, the goal of this project will be to identify the aminopeptidase mechanisms responsible for generating neurotoxic pGluA¿ that participates with A ¿ in development of AD. Results can provide novel protease targets for Alzheimer's disease. The hypothesis of this project is that the aspartate aminopeptidase and alanine aminopeptidase enzymes generate A ¿ (3-40/42) which is converted to pGluA¿(3-40/42) by glutaminyl cyclase (QC). This hypothesis is supported by our preliminary data demonstrating the presence of aspartate and alanine aminopeptidase activities in secretory vesicles that contain pGluA¿ (3-40/42) and A¿ (1-40/42). This hypothesis will be assessed in three specific aims to (1) identify aspartate and alanine aminopeptidases in A ¿ -producing secretory vesicles that remove the N-terminal Asp and Ala residues from A ¿ (1-40/42), (2) evaluate identified aminopeptidases by gene silencing and expression for their roles in producing pGluA¿ (3-40/42), and (3) evaluate inhibitors of these aminopeptidase activities to reduce production of pGluA¿ (3- 40/42). This project will identify new aminopeptidase mechanisms for producing neurotoxic pGluA¿ peptides. Results will also yield candidate inhibitors of these aminopeptidases for future investigation of aminopeptidase regulation in Alzheimer's disease.

描述（由申请人提供）：β-淀粉样蛋白（A <$）的N-末端截短焦谷氨酸（pGlu）修饰形式pGluA <$（3-40/42）（简称pGluA <$）在阿尔茨海默病中显示出高神经毒性、神经变性和记忆丧失。值得注意的是，pGluA在AD脑中丰富，并且以大于A的水平存在（1-40/42）。pGluA <$加速A <$和pGluA <$寡聚体的形成，导致AD中的神经毒性细胞死亡和记忆缺陷。pGluA <$（3-40/42）肽开始于N-末端谷氨酸，A <$（1-40/42）的第三个氨基酸。pGluA通过氨基肽酶从A？（1-40/42）产生肽，氨基肽酶去除N-末端天冬氨酸和丙氨酸残基，然后环化N-末端谷氨酸。产生pGluA肽所需的氨肽酶尚未阐明。因此，本项目的目标是确定负责产生神经毒性pGluA <$的氨肽酶机制，该机制与A <$一起参与AD的发展。结果可以为阿尔茨海默病提供新的蛋白酶靶点。本项目的假设是天冬氨酸氨肽酶和丙氨酸氨肽酶产生A <$（3-40/42），A <$（3 - 40/42）被β-氨基环化酶（QC）转化为pGluA <$（3-40/42）。这一假设得到了我们的初步数据的支持，这些数据表明在含有pGluA <$（3-40/42）和A <$（1-40/42）的分泌囊泡中存在天冬氨酸和丙氨酸氨肽酶活性。这一假设将在三个具体目标中进行评估，以（1）鉴定产生A <$的分泌囊泡中的天冬氨酸和丙氨酸氨基肽酶，这些酶从A <$（1-40/42）去除N-末端Asp和Ala残基，（2）通过基因沉默和表达评估鉴定的氨基肽酶在产生pGluA <$中的作用（3-40/42）和（3）评价这些氨肽酶活性的抑制剂以减少pGluA？的产生（3- 40/42）。该项目将确定产生神经毒性pGluA肽的新氨肽酶机制。结果也将产生这些氨肽酶的候选抑制剂，用于将来研究阿尔茨海默病的氨肽酶调节。